Now, the pharmaceutical business. A curious place, brimming with promises and, let’s be honest, a fair bit of hocus-pocus. People are always chasing the next miracle cure, and the companies selling them? Well, they’re rather like greedy little goblins, aren’t they, hoarding their secrets and polishing their profits.
Remember Pfizer? Back in 2020, they had a bit of a lucky streak, didn’t they? A certain virus came along, and suddenly, their shares were shooting upwards like rockets. From a measly $33 to nearly $60! For a short while, they were the golden geese of the stock market. But geese, as anyone knows, don’t stay golden forever.
The demand for their potion faded, and the price began to tumble. It’s now hovering around $28, lower than it was before all the fuss. A cautionary tale, really. Chasing temporary booms is like building a house of cards – thrilling for a moment, but utterly doomed.
You see, these drug companies are terribly reliant on something called a ‘patent’. It’s a bit like a magical shield, protecting their creations from being copied. But the shield only lasts for about 20 years. And because it takes ages to actually make the potion, much of that time is used up before it even hits the shelves. So, they get a mere 10 or 12 years of exclusive profit-grabbing. It’s rather unfair, don’t you think?
The Pipeline Problem
This means they must constantly be concocting new potions, filling their ‘pipelines’, as they call it. They need the next blockbuster drug, the one that will send their profits soaring. Otherwise, they’re in a spot of bother.
And that brings us to Eli Lilly. They seem to be rather good at this pipeline business. They’ve cornered the market in a new type of potion – a GLP-1, they call it – that helps with blood sugar and weight loss. A rather clever bit of chemistry, if you ask me.
But they’re not stopping there. Oh no. They’ve just swallowed up a company called Orna Therapeutics for $2.4 billion. This Orna, it seems, can fiddle with a patient’s genes and cells – inside their bodies, not in some gloomy laboratory. A bit spooky, if you ask me, but potentially very lucrative.
And just before that, they paid $350 million for a collaboration with a Chinese company, and another billion for a German one. All to develop treatments for nasty things like immune disorders and cancer. They’re gobbling up smaller companies like a hungry caterpillar. A rather aggressive strategy, but it might just work.
It’s this sort of foresight, this constant quest for the next miracle, that keeps a drug stock moving upwards. But remember, my dear readers, even the most potent potion can lose its fizz. The market is a fickle beast, and fortunes can change in a blink. So, approach with caution, and don’t believe everything you’re told. Especially by goblins.
Read More
- 2025 Crypto Wallets: Secure, Smart, and Surprisingly Simple!
- 20 Films Where the Opening Credits Play Over a Single Continuous Shot
- Gold Rate Forecast
- 50 Serial Killer Movies That Will Keep You Up All Night
- Here Are the Best TV Shows to Stream this Weekend on Paramount+, Including ‘48 Hours’
- ‘The Substance’ Is HBO Max’s Most-Watched Movie of the Week: Here Are the Remaining Top 10 Movies
- 17 Black Voice Actors Who Saved Games With One Line Delivery
- PLURIBUS’ Best Moments Are Also Its Smallest
- Top gainers and losers
- 20 Movies to Watch When You’re Drunk
2026-02-14 22:32